Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2026 09:15 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
March 25, 2026 02:00 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes

In a phase 2 trial in Chinese people with T2D, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean weight reduction of up to of up to 9.8% ...
March 18, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
March 17, 2026 06:00 ET | Source: Priavoid GmbH

Priavoid Presents Initial Phase 2 Data Suggesting Favorable Safety Profile for Alzheimer’s Candidate PRI-002 at AD/PD™ 2026

Blinded safety data from the ongoing Phase 2 trial suggest no treatment-related amyloid-related imaging abnormalities (ARIA) with PRI-002 Drug Safety and Monitoring Board recommended continued...
March 05, 2026 05:00 ET | Source: Priavoid GmbH

Priavoid to Present Initial Phase 2 Safety Data for Alzheimer‘s and Preclinical PoC for Parkinson‘s Programs at AD/PD™ 2026

Dusseldorf, Germany, March 5, 2026 - Priavoid GmbH (“Priavoid”) today announced it will present promising initial safety data from the ongoing Phase 2 trial (PRImus-AD, NCT06182085) evaluating its...
February 25, 2026 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
February 19, 2026 10:35 ET | Source: Herantis Pharma plc

Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096

Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations Espoo, Finland, 19 February 2026: Herantis Pharma...
January 09, 2026 06:00 ET | Source: Mutuum Finance

Mutuum Finance (MUTM) Advances Through Roadmap Phase 2 with Over $19.6M Raised

DUBAI, United Arab Emirates, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In DeFi, roadmap progress often matters more than short-term price moves. Projects that build first usually attract attention later....
December 17, 2025 08:45 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid...
December 16, 2025 06:00 ET | Source: McEwen Inc.

McEwen Secures Key Permit for El Gallo Mine; Mill Construction to Begin Mid-2026 - First Gold Pour Mid-2027

TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- McEwen Inc. (NYSE/TSX: MUX) (“McEwen” or the “Company”) is pleased to announce that the extension of its Environmental Impact Assessment (Manifestación de...